Equity Investment Corp Has $127.17 Million Holdings in Sanofi $SNY

Equity Investment Corp raised its position in shares of Sanofi (NASDAQ:SNY) by 1.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,624,212 shares of the company’s stock after purchasing an additional 36,522 shares during the quarter. Sanofi accounts for about 2.6% of Equity Investment Corp’s investment portfolio, making the stock its 10th biggest holding. Equity Investment Corp’s holdings in Sanofi were worth $127,169,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of SNY. Advisory Services Network LLC lifted its holdings in Sanofi by 1.4% during the third quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock valued at $743,000 after purchasing an additional 210 shares in the last quarter. Savant Capital LLC lifted its holdings in Sanofi by 2.7% during the fourth quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock valued at $418,000 after purchasing an additional 225 shares in the last quarter. Wesbanco Bank Inc. lifted its holdings in Sanofi by 4.9% during the fourth quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock valued at $239,000 after purchasing an additional 230 shares in the last quarter. IFG Advisory LLC lifted its holdings in Sanofi by 2.7% during the fourth quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock valued at $446,000 after purchasing an additional 244 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Sanofi by 5.5% during the fourth quarter. GAMMA Investing LLC now owns 5,058 shares of the company’s stock valued at $245,000 after purchasing an additional 264 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on SNY shares. BNP Paribas Exane downgraded shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a report on Monday, April 20th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Argus upgraded shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Morgan Stanley set a $52.00 price objective on shares of Sanofi in a research report on Friday, May 1st. Finally, Bank of America cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Sanofi has a consensus rating of “Hold” and an average price target of $51.00.

Sanofi Trading Up 1.2%

Shares of SNY opened at $44.11 on Friday. The company’s fifty day moving average is $45.21 and its 200 day moving average is $46.56. Sanofi has a fifty-two week low of $42.28 and a fifty-two week high of $52.68. The stock has a market capitalization of $106.94 billion, a PE ratio of 12.32, a P/E/G ratio of 1.07 and a beta of 0.34. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were given a $2.4225 dividend. This is a boost from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. The ex-dividend date was Monday, May 4th. Sanofi’s dividend payout ratio (DPR) is presently 49.16%.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.